Effects of Involvement in a Group-based Creative Expression Program on Psychotropic Drug Use in Persons With Dementia
This project, a small-scale pilot study, will attempt to determine if involvement in a group-based creative expression program may correlate with a reduction in use of psychotropic drugs for persons with dementia.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
|Official Title:||Effects of Involvement in a Group-based Creative Expression Program on Psychotropic Drug Use in Persons With Dementia in Long-term Care: a Cluster-randomized Pilot Study|
- Rates of psychotropic drug prescriptions for study participants. [ Time Frame: eight months ] [ Designated as safety issue: No ]
- Mood and behavior patterns [ Time Frame: eight months ] [ Designated as safety issue: No ]
|Study Start Date:||June 2011|
|Study Completion Date:||September 2011|
|Primary Completion Date:||July 2011 (Final data collection date for primary outcome measure)|
|Experimental: TimeSlips group storytelling program||
TimeSlips is a group-based creative storytelling program for people with dementia. The intervention will be held twice a week for six weeks, in hour-long sessions.
|Active Comparator: Standard care activity program||
Behavioral: Standard care activity program
Standard-of-care activities for the study site's skilled-nursing dementia Special Care Units.
The study site has two skilled-nursing dementia Special Care Units. One unit will serve as a control with residents receiving the standard care activity program. The other unit will receive the standard care activity program as well as the TimeSlips storytelling program (two hour-long sessions per week for six weeks). The behavioral symptoms and psychotropic drug usage for both cohorts will be studied for eight months, the first four months with no intervention and the last four months with or without the six-week TimeSlips intervention.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01382693
|United States, Pennsylvania|
|Lititz, Pennsylvania, United States, 17543|
|Principal Investigator:||Winona S Houser, BA||Penn State College of Medicine, Penn State Milton S. Hershey Medical Center|
|Study Director:||Daniel R George, PhD||Penn State College of Medicine, Penn State Milton S. Hershey Medical Center|